InvestorsHub Logo
Followers 7
Posts 125
Boards Moderated 0
Alias Born 05/10/2016

Re: fred198484 post# 20339

Thursday, 02/22/2018 8:14:04 AM

Thursday, February 22, 2018 8:14:04 AM

Post# of 232888
Fred,
Your ability to read between the actual facts and find the “real” story is outstanding to say the least. How lucky we all are to have you to save us all from being blindly misled by the data and press releases. You are certainly the most credible of our available resources, and your opinion is obviously very valuable. Speaking of credible opinions, may I offer two more sources...

“These data clearly demonstrate the anti-HIV-1 activity of PRO 140 in antiretroviral treatment-experienced individuals who were documented to have ongoing virus replication in the face of therapy with currently approved drugs,” said Scott M. Hammer, MD, Harold C. Neu Professor and Chief of the Division of Infectious Diseases, Columbia University Medical Center/New York-Presbyterian Hospital. “Antiviral drug resistance is an ongoing threat to HIV infected persons. Despite the dramatic progress in treatment success over the course of the epidemic, we cannot be complacent. Agents with different mechanisms of action, modes of delivery, and frequencies of administration are needed to provide patients with the options necessary to achieve and sustain virologic suppression. PRO 140 is a clear example of the advances in HIV therapeutics that can result from the dedication of developers, patients and providers to this principle.”

“The standard approach to ART therapy has been to administer combinations of oral medications that must be taken daily,” said Robert T. Schooley, MD, Professor of Medicine, Department of Infectious Diseases and Global Public Health, University of California, San Diego. “Recently, there has been increasing interest in the development of drugs that do not require daily administration. I believe that PRO 140 is a step in that direction. These PRO 140 trial findings support the potential of managing HIV by blocking its entry into T cells through a novel humanized monoclonal antibody administered in weekly subcutaneous injections. PRO 140 could provide an important new therapeutic option in suppressing a patient’s viral load as well as deterring the spread of this disease.”

Maybe you could reach out to both of these uneducated professionals to enlighten them with your wisdom as well. Again, thank you for your contributions and saving us all from being overwhelmed by the facts.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News